BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cosola C, Rocchetti MT, Cupisti A, Gesualdo L. Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease. Pharmacol Res. 2018;130:132-142. [PMID: 29518493 DOI: 10.1016/j.phrs.2018.03.003] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Kanemitsu Y, Mishima E, Maekawa M, Matsumoto Y, Saigusa D, Yamaguchi H, Ogura J, Tsukamoto H, Tomioka Y, Abe T, Mano N. Comprehensive and semi-quantitative analysis of carboxyl-containing metabolites related to gut microbiota on chronic kidney disease using 2-picolylamine isotopic labeling LC-MS/MS. Sci Rep 2019;9:19075. [PMID: 31836785 DOI: 10.1038/s41598-019-55600-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Chen Q, Ma X, Li C, Shen Y, Zhu W, Zhang Y, Guo X, Zhou J, Liu C. Enteric Phageome Alterations in Patients With Type 2 Diabetes. Front Cell Infect Microbiol 2020;10:575084. [PMID: 33552999 DOI: 10.3389/fcimb.2020.575084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cosola C, Sabatino A, di Bari I, Fiaccadori E, Gesualdo L. Nutrients, Nutraceuticals, and Xenobiotics Affecting Renal Health. Nutrients 2018;10:E808. [PMID: 29937486 DOI: 10.3390/nu10070808] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Noce A, Marrone G, Di Daniele F, Ottaviani E, Wilson Jones G, Bernini R, Romani A, Rovella V. Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases. Nutrients 2019;11:E1073. [PMID: 31091761 DOI: 10.3390/nu11051073] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 15.3] [Reference Citation Analysis]
5 Aydin S, Ugur K, Aydin S. Could excessive production of tyramine by the microbiota be a reason for essential hypertension? Biosci Microbiota Food Health 2018;37:77-8. [PMID: 30370190 DOI: 10.12938/bmfh.18-010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Shen L, Shen K, Bai J, Wang J, Singla RK, Shen B. Data-driven microbiota biomarker discovery for personalized drug therapy of cardiovascular disease. Pharmacol Res 2020;161:105225. [PMID: 33007417 DOI: 10.1016/j.phrs.2020.105225] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hu X, Ouyang S, Xie Y, Gong Z, Du J. Characterizing the gut microbiota in patients with chronic kidney disease. Postgrad Med 2020;132:495-505. [PMID: 32241215 DOI: 10.1080/00325481.2020.1744335] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Bryniarski MA, Hamarneh F, Yacoub R. The role of chronic kidney disease-associated dysbiosis in cardiovascular disease. Exp Biol Med (Maywood) 2019;244:514-25. [PMID: 30682892 DOI: 10.1177/1535370219826526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
9 Hu X, Xie Y, Xiao Y, Zeng W, Gong Z, Du J. Longitudinal analysis of fecal microbiome and metabolome during renal fibrotic progression in a unilateral ureteral obstruction animal model. Eur J Pharmacol 2020;886:173555. [PMID: 32937112 DOI: 10.1016/j.ejphar.2020.173555] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Ali BH, Al Za'abi M, Al Suleimani Y, Manoj P, Ali H, Ribeiro DA, Nemmar A. Gum arabic reduces inflammation, oxidative, and nitrosative stress in the gastrointestinal tract of mice with chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol 2020;393:1427-36. [PMID: 32157347 DOI: 10.1007/s00210-020-01844-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Fiaccadori E, Cosola C, Sabatino A. Targeting the Gut for Early Diagnosis, Prevention, and Cure of Diabetic Kidney Disease: Is the Phenyl Sulfate Story Another Step Forward? Am J Kidney Dis 2020;75:144-7. [PMID: 31451331 DOI: 10.1053/j.ajkd.2019.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Cupisti A, Bolasco P, D'Alessandro C, Giannese D, Sabatino A, Fiaccadori E. Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients. Toxins (Basel) 2021;13:289. [PMID: 33921862 DOI: 10.3390/toxins13040289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sumida K, Kovesdy C. The gut–kidney–heart axis in chronic kidney disease. Physiol Int 2019;106:195-206. [DOI: 10.1556/2060.106.2019.19] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
14 Kuro-o M. Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardiovascular complications? Nephrology Dialysis Transplantation 2019;34:15-21. [DOI: 10.1093/ndt/gfy126] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
15 Wei W, Ma N, Fan X, Yu Q, Ci X. The role of Nrf2 in acute kidney injury: Novel molecular mechanisms and therapeutic approaches. Free Radic Biol Med 2020;158:1-12. [PMID: 32663513 DOI: 10.1016/j.freeradbiomed.2020.06.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Mafra D, Borges N, Alvarenga L, Esgalhado M, Cardozo L, Lindholm B, Stenvinkel P. Dietary Components That May Influence the Disturbed Gut Microbiota in Chronic Kidney Disease. Nutrients 2019;11:E496. [PMID: 30818761 DOI: 10.3390/nu11030496] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 15.7] [Reference Citation Analysis]
17 Crowley EK, Long-Smith CM, Murphy A, Patterson E, Murphy K, O'Gorman DM, Stanton C, Nolan YM. Dietary Supplementation with a Magnesium-Rich Marine Mineral Blend Enhances the Diversity of Gastrointestinal Microbiota. Mar Drugs 2018;16:E216. [PMID: 29925774 DOI: 10.3390/md16060216] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
18 Rocchetti MT, Di Iorio BR, Vacca M, Cosola C, Marzocco S, di Bari I, Calabrese FM, Ciarcia R, De Angelis M, Gesualdo L. Ketoanalogs' Effects on Intestinal Microbiota Modulation and Uremic Toxins Serum Levels in Chronic Kidney Disease (Medika2 Study). J Clin Med 2021;10:840. [PMID: 33670711 DOI: 10.3390/jcm10040840] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Cosola C, Rocchetti MT, Sabatino A, Fiaccadori E, Di Iorio BR, Gesualdo L. Microbiota issue in CKD: how promising are gut-targeted approaches? J Nephrol 2019;32:27-37. [PMID: 30069677 DOI: 10.1007/s40620-018-0516-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
20 Di Iorio BR, Rocchetti MT, De Angelis M, Cosola C, Marzocco S, Di Micco L, di Bari I, Accetturo M, Vacca M, Gobbetti M, Di Iorio M, Bellasi A, Gesualdo L. Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study). J Clin Med 2019;8:E1424. [PMID: 31510015 DOI: 10.3390/jcm8091424] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
21 Bostanghadiri N, Ziaeefar P, Sameni F, Mahmoudi M, Hashemi A, Darban-Sarokhalil D. The controversial association of gut and urinary microbiota with kidney stone formation. Microb Pathog 2021;161:105257. [PMID: 34687841 DOI: 10.1016/j.micpath.2021.105257] [Reference Citation Analysis]
22 Matsumoto T, Takayanagi K, Kojima M, Taguchi K, Kobayashi T. Acute Exposure to Indoxyl Sulfate Impairs Endothelium-Dependent Vasorelaxation in Rat Aorta. Int J Mol Sci 2019;20:E338. [PMID: 30650577 DOI: 10.3390/ijms20020338] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
23 Salvadori M, Tsalouchos A. Microbiota, renal disease and renal transplantation. World J Transplant 2021; 11(3): 16-36 [PMID: 33816144 DOI: 10.5500/wjt.v11.i3.16] [Reference Citation Analysis]
24 Dos Santos Ramos A, Viana GCS, de Macedo Brigido M, Almeida JF. Neutrophil extracellular traps in inflammatory bowel diseases: Implications in pathogenesis and therapeutic targets. Pharmacol Res 2021;171:105779. [PMID: 34298111 DOI: 10.1016/j.phrs.2021.105779] [Reference Citation Analysis]
25 Cosola C, Rocchetti MT, di Bari I, Acquaviva PM, Maranzano V, Corciulo S, Di Ciaula A, Di Palo DM, La Forgia FM, Fontana S, De Angelis M, Portincasa P, Gesualdo L. An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients. Toxins (Basel) 2021;13:334. [PMID: 34063068 DOI: 10.3390/toxins13050334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Caggiano G, Cosola C, Di Leo V, Gesualdo M, Gesualdo L. Microbiome modulation to correct uremic toxins and to preserve kidney functions. Curr Opin Nephrol Hypertens 2020;29:49-56. [PMID: 31725010 DOI: 10.1097/MNH.0000000000000565] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
27 Armani RG, Carvalho AB, Ramos CI, Hong V, Bortolotto LA, Cassiolato JL, Oliveira NF, Cieslarova Z, do Lago CL, Klassen A, Cuppari L, Raj DS, Canziani MEF. Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial. Nephrol Dial Transplant 2021:gfaa335. [PMID: 33411910 DOI: 10.1093/ndt/gfaa335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chen W, Zhang S, Wu J, Ye T, Wang S, Wang P, Xing D. Butyrate-producing bacteria and the gut-heart axis in atherosclerosis. Clin Chim Acta 2020;507:236-41. [PMID: 32376324 DOI: 10.1016/j.cca.2020.04.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
29 Zaidan N, Nazzal L. The Microbiome and Uremic Solutes. Toxins 2022;14:245. [DOI: 10.3390/toxins14040245] [Reference Citation Analysis]
30 Cupisti A, Gallieni M, Avesani CM, D'Alessandro C, Carrero JJ, Piccoli GB. Medical Nutritional Therapy for Patients with Chronic Kidney Disease not on Dialysis: The Low Protein Diet as a Medication. J Clin Med 2020;9:E3644. [PMID: 33198365 DOI: 10.3390/jcm9113644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Collado MC, Vinderola G, Salminen S. Postbiotics: facts and open questions. A position paper on the need for a consensus definition. Benef Microbes 2019;10:711-9. [PMID: 31965850 DOI: 10.3920/BM2019.0015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 10.3] [Reference Citation Analysis]
32 Peluzio MDCG, Martinez JA, Milagro FI. Postbiotics: Metabolites and mechanisms involved in microbiota-host interactions. Trends in Food Science & Technology 2021;108:11-26. [DOI: 10.1016/j.tifs.2020.12.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 16.0] [Reference Citation Analysis]
33 Tani M, Tanaka S, Takamiya K, Kato Y, Harata G, He F, Sakaue M, Ito M. Effects of dietary fiber on vascular calcification by repetitive diet-induced fluctuations in plasma phosphorus in early-stage chronic kidney disease rats. J Clin Biochem Nutr 2020;67:283-9. [PMID: 33293769 DOI: 10.3164/jcbn.20-46] [Reference Citation Analysis]
34 Plata C, Cruz C, Cervantes LG, Ramírez V. The gut microbiota and its relationship with chronic kidney disease. Int Urol Nephrol 2019;51:2209-26. [PMID: 31576489 DOI: 10.1007/s11255-019-02291-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
35 Rocchetti MT. New Strategies for the Reduction of Uremic Toxins: How Much More We Know. Toxins (Basel) 2021;13:837. [PMID: 34941675 DOI: 10.3390/toxins13120837] [Reference Citation Analysis]
36 Chen H, Wang MC, Chen YY, Chen L, Wang YN, Vaziri ND, Miao H, Zhao YY. Alisol B 23-acetate attenuates CKD progression by regulating the renin-angiotensin system and gut-kidney axis. Ther Adv Chronic Dis 2020;11:2040622320920025. [PMID: 32547719 DOI: 10.1177/2040622320920025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Paats J, Adoberg A, Arund J, Dhondt A, Fernström A, Fridolin I, Glorieux G, Leis L, Luman M, Gonzalez-Parra E, Perez-Gomez VM, Pilt K, Sanchez-Ospina D, Segelmark M, Uhlin F, Arduan Ortiz A. Serum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD Patients. Int J Mol Sci 2020;21:E1522. [PMID: 32102247 DOI: 10.3390/ijms21041522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Rocchetti MT, Cosola C, di Bari I, Magnani S, Galleggiante V, Scandiffio L, Dalfino G, Netti GS, Atti M, Corciulo R, Gesualdo L. Efficacy of Divinylbenzenic Resin in Removing Indoxyl Sulfate and P-Cresol Sulfate in Hemodialysis Patients: Results From an In Vitro Study and An In Vivo Pilot Trial (xuanro4-Nature 3.2). Toxins (Basel) 2020;12:E170. [PMID: 32164382 DOI: 10.3390/toxins12030170] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
39 Esperanza MG, Wrobel K, Ojeda AG, Garay-Sevilla ME, Escobosa ARC, Barrientos EY, Wrobel K. Liquid chromatography-mass spectrometry untargeted metabolomics reveals increased levels of tryptophan indole metabolites in urine of metabolic syndrome patients. Eur J Mass Spectrom (Chichester) 2020;26:379-87. [PMID: 33295818 DOI: 10.1177/1469066720964632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Kuro-O M. The Klotho proteins in health and disease. Nat Rev Nephrol 2019;15:27-44. [PMID: 30455427 DOI: 10.1038/s41581-018-0078-3] [Cited by in Crossref: 136] [Cited by in F6Publishing: 139] [Article Influence: 45.3] [Reference Citation Analysis]
41 Perna AF, Glorieux G, Zacchia M, Trepiccione F, Capolongo G, Vigorito C, Anishchenko E, Ingrosso D. The role of the intestinal microbiota in uremic solute accumulation: a focus on sulfur compounds. J Nephrol 2019;32:733-40. [PMID: 30673975 DOI: 10.1007/s40620-019-00589-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
42 Sabatino A, Piotti G, Cosola C, Gandolfini I, Kooman J, Fiaccadori E. Dietary protein and nutritional supplements in conventional hemodialysis. Semin Dial 2018;31:583-91. [DOI: 10.1111/sdi.12730] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
43 Pieniazek A, Bernasinska-Slomczewska J, Gwozdzinski L. Uremic Toxins and Their Relation with Oxidative Stress Induced in Patients with CKD. Int J Mol Sci 2021;22:6196. [PMID: 34201270 DOI: 10.3390/ijms22126196] [Reference Citation Analysis]
44 Koszewicz M, Jaroch J, Brzecka A, Ejma M, Budrewicz S, Mikhaleva LM, Muresanu C, Schield P, Somasundaram SG, Kirkland CE, Avila-Rodriguez M, Aliev G. Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment. Pharmacol Res 2021;164:105277. [PMID: 33166735 DOI: 10.1016/j.phrs.2020.105277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]